{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Effects of peptides derived from BACE1 catalytic domain on APP processing",
      "version": "1.0.0",
      "authors": "Rana Aldisi",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/yeon2007.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 40",
      "id": "2ca2eb795438fe9e0f24c1e9d332717de5e344ddfee00ce8df89c5b901d85db5994d6ffd383e40a90bde264f33e75b220476b3de86c89f0658bf281c872f0bb6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "sAPP-alpha",
      "id": "7e0d346932e47222255dbd0e3b132a0dbeb5ba12373ac498350cabcb9d55c68f9de35471d8a7b9d9ac04e97b62b9699eef7226e0a7827d4b6be0d24acb31e70e"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "sAPP-beta",
      "id": "d9a13b7f8a013052f02bb7565cbc8f19ecfe3d2b91b0a859805ee7f6daae87a1c0f9e767d7352034aebb75abeb68b719aa3bef41942ef643d69b858b0b7f148c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ACTB",
      "id": "864075cc768b94b4d2a2cce42edbc91b6e061b9abe2f2094979f2292b4df0482e48e5033c755c18db80fb42d276d030b6be6b2f959c501cd66ddafb09c390775"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "id": "88f17e7dffb6947c01414f79e5a3bb9cdd3e932c355af7f0c8907d2b5d07742883eaf63866fe7fc938401ce0c366856fd5e306f324e6c1f474c1a984c8e46a51"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "variants": [
        {
          "kind": "frag",
          "start": 228,
          "stop": 236
        }
      ],
      "id": "347d07b2dcdfa0ae9783627608d4505222452f7d93f35797591a31633c741a87ee740b1701e2b07f9bfe2a63520c64251a6818d53653ede3f7920a4a8b49726a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "variants": [
        {
          "kind": "frag",
          "start": 230,
          "stop": 235
        }
      ],
      "id": "a76c7c55e5b6461e341ee803d5727ffdaa564a8099f5cb8b93cab42285064f7c3f7d595261cd0188693d2f8d56583e6719ba408e632760806d6f3bc429c5b9e3"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "variants": [
        {
          "kind": "frag",
          "start": 67,
          "stop": 78
        }
      ],
      "id": "d0990ccdebd9bc600ee3de18fe5729aa78fe778fb2050e04f56ec41ae5e96a3b01f1211e3c51382f87f5c1d095bd7c885d6652e8f7dfbec97ed4115bdfabf9f2"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "variants": [
        {
          "kind": "frag",
          "start": 69,
          "stop": 75
        }
      ],
      "id": "12cf7a54497c1e55343ea73a2c068f06dad7524cebb00d67833a310fe005a77ea03da024eb16a35ce400b0de6970ab4fc660898b2cf61f46746e3e51a60042ab"
    }
  ],
  "links": [
    {
      "line": 91,
      "relation": "decreases",
      "evidence": "BI-1 treatment dose-dependently inhibited the release of both sAPPa and sAPPb in the conditioned medium (Figs. 2A and 3A). The 50% inhibitory concentrations (IC50) of BI-1 were about 1.5 mM for sAPPa and 0.9 mM for APPb, respectively. But BI-2, which is mainly composed of the core region BACE1 69–73, did not show the inhibitory effects",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 8,
      "target": 3,
      "key": "401c486e233ab95551998e9d2a72e34163bf864c8ecc32e5d98afe545309321c91a4650b52354a8eec74e341e2bbb1d44500514655a0243e96f937c974aec5c2"
    },
    {
      "line": 136,
      "relation": "decreases",
      "evidence": "Taken together, these results show that BI-1 and BI-3 not only selectively reduce the level of APPbeta but also lead to the accumulation of APPalpha in cells with no change of full-length APP level.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 8,
      "target": 3,
      "key": "3375b2f19f6dd443d98ad07829efda05212ed01e65e4f0a128e2bd6e32fa0bfa31936160342c98b086f7567a83481ed84a8422891d4f209840a8563abe99233c"
    },
    {
      "line": 92,
      "relation": "decreases",
      "evidence": "BI-1 treatment dose-dependently inhibited the release of both sAPPa and sAPPb in the conditioned medium (Figs. 2A and 3A). The 50% inhibitory concentrations (IC50) of BI-1 were about 1.5 mM for sAPPa and 0.9 mM for APPb, respectively. But BI-2, which is mainly composed of the core region BACE1 69–73, did not show the inhibitory effects",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 8,
      "target": 2,
      "key": "dbce939e6aec69f75e787ed8ac400baa3703706782333ecef8bfa1f2179795531012fbfff722dfcc1c3f605d80b6a9889ae17e20d36db452d4d50e09d6677811"
    },
    {
      "line": 113,
      "relation": "increases",
      "evidence": "Surprisingly, BI-1 treatment resulted in a drastic, dose-dependent increase in the level of intracellular APPa (Figs. 2A and 3A). BI-3 also induced the accumulation of intracellular APPa until the concentration of BI-3 was raised to 12.5 mM; however, treatment of BI-3 with 25 mM decreased the level of intracellular APPa.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "intracellular"
        }
      },
      "source": 8,
      "target": 2,
      "key": "dfd3cc3be285e8b19222775808247ecdefbe27ec5213357ffaf60c2000b0491189dcddcf96a51be8f62a61e3eb0793c061d5cddd5f2fb1c88bee9dfd6af3349e"
    },
    {
      "line": 138,
      "relation": "increases",
      "evidence": "Taken together, these results show that BI-1 and BI-3 not only selectively reduce the level of APPbeta but also lead to the accumulation of APPalpha in cells with no change of full-length APP level.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 8,
      "target": 2,
      "key": "83149e50316f8a8fa86060c16b0367f40d9a37207ff517c5837394c6fa67b4654129565da1a67db1d8197cae20827b069ac9e0b22941567254304aebd895edb4"
    },
    {
      "line": 121,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 8,
      "target": 1,
      "key": "c1f690d15435917a18b400c9e5c4e5d874f26074b4ae7e21ff02777a8a136c6a0394aa854709d787b383b9082f7c0ed7f550ea3ccb62e753c2733cdb1dc473ab"
    },
    {
      "line": 126,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 8,
      "target": 4,
      "key": "5153bf4e92aa5c481dfb3794199c8874f77094cd82d27f779f423315df8e87f97ad2fb20216c9d9a80b50d291f40ecebc1ec5bf7754a8e0d5da3337406cf18f1"
    },
    {
      "line": 147,
      "relation": "causesNoChange",
      "evidence": "These results suggest that BACE1 derived peptides do not directly inhibit BACE activities in vitro when the fluorogenic peptides are used as a substrate.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 8,
      "target": 5,
      "key": "3d8f75f4faedbf1f05a4331957259f7f2a9423d6a6eba4622f7584d92f1ff536953756ef7aaadeb54edc6e4962047d44b4c41b9fea171343cc1c9bc6fc357f77"
    },
    {
      "line": 155,
      "relation": "decreases",
      "evidence": "BI-1 treatment effectively reduced Ab 40 levels (IC50 = 0.06 mM) in the conditioned medium. BI-3 also inhibited Ab 40 production (IC50 = 0.2 mM), although the effective concentrations were relatively high compared to those of BI-1.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 8,
      "target": 0,
      "key": "3b50d1aaa151b1471f8bd8f1ab3c1d67aac9081239ab91931bbfb0b0ce33c8db29080aeea60bace2e4e9a1ef29f545c5e596202d614168c717dac564aa615122"
    },
    {
      "relation": "hasVariant",
      "source": 5,
      "target": 8,
      "key": "3d1df720f4523fdfa153c3badeb9633241d34873ccd5ffe56f9d866d307b33c0baec8c6fbd868997ea76f2c836d8f01f83a32b3c51de2631fa643b0aee946fe0"
    },
    {
      "relation": "hasVariant",
      "source": 5,
      "target": 9,
      "key": "06dc9c8ebe0e21543c7bd4d16f7fe4b1f6cf523543a9fe3f111006d8cc646acceceab4b594d7e0ba5d926239b8003db780e3d7a08d1aaafb46715b6973d6fe8d"
    },
    {
      "relation": "hasVariant",
      "source": 5,
      "target": 6,
      "key": "13ad4e9eb7ccf275ba5e644bbdffa6d495ba134a27dd909eac1c6c791047b35acceda90b566127730db83836f4cebe737c5cd4a9ee88d34b04c99b3fac8abe62"
    },
    {
      "relation": "hasVariant",
      "source": 5,
      "target": 7,
      "key": "b2dec348a60ea19882285f2600a7bab14581daa79075ea35e284f07fc93062674b74d5618bda09d7111951e4478aeed605f35614e705b77b51355b34ce1801a0"
    },
    {
      "line": 93,
      "relation": "causesNoChange",
      "evidence": "BI-1 treatment dose-dependently inhibited the release of both sAPPa and sAPPb in the conditioned medium (Figs. 2A and 3A). The 50% inhibitory concentrations (IC50) of BI-1 were about 1.5 mM for sAPPa and 0.9 mM for APPb, respectively. But BI-2, which is mainly composed of the core region BACE1 69–73, did not show the inhibitory effects",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 9,
      "target": 3,
      "key": "67f7ceba9978346be8a3d027f0a899cd93008b5ef90403dd17f7b840307c18a80ad9ccc3a8fc3a935d0094ae24b35763a38a6f3247559a41bcc885d0841ccd25"
    },
    {
      "line": 94,
      "relation": "causesNoChange",
      "evidence": "BI-1 treatment dose-dependently inhibited the release of both sAPPa and sAPPb in the conditioned medium (Figs. 2A and 3A). The 50% inhibitory concentrations (IC50) of BI-1 were about 1.5 mM for sAPPa and 0.9 mM for APPb, respectively. But BI-2, which is mainly composed of the core region BACE1 69–73, did not show the inhibitory effects",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 9,
      "target": 2,
      "key": "42b4459e70af6f9a6f3b09d01859676d43474b0f5d2a4412556a3e868a27fadc613186ce0d513e16f4955d71fb50b08543226b97886154ff715293baad951f8e"
    },
    {
      "line": 122,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 9,
      "target": 1,
      "key": "60d25dc50a87b0abc79acdb4eeafd2f8f2acc7f5f064ad9415262cb48fb1675175f9bb5d98a7d1f0583609a0b499217ac76dce39e82d2ad61c23adba154c4e6a"
    },
    {
      "line": 127,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 9,
      "target": 4,
      "key": "3d63a0d25e68241414f9afc962af684399402e07b3fb225901d36886b3c4bd44ab1cec5bcf3d6e149146d531acc81e60177619c4219b0488f3acd5ab436c8c4c"
    },
    {
      "line": 101,
      "relation": "decreases",
      "evidence": "BI-3 also potentially inhibited the release of sAPPb (IC50 = 0.5 mM) and sAPPa (IC50 = 3.4 mM, Figs. 2B and 3B). BI- 4, which is short peptide of BI-3, showed no effects on sAPP secretion.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 6,
      "target": 3,
      "key": "c5005af726d4ea88a7ce153439a0c164e69ab64de2b876a477f4f067b0263e0f795dd1168393aa5f972bc928be2842ef5d2458e9dd28b33ff7f8cb85f2cd6981"
    },
    {
      "line": 137,
      "relation": "decreases",
      "evidence": "Taken together, these results show that BI-1 and BI-3 not only selectively reduce the level of APPbeta but also lead to the accumulation of APPalpha in cells with no change of full-length APP level.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 6,
      "target": 3,
      "key": "5f52e0e7c5404f68d8bcb2530b807591c987a59d2e9987593d05ca013bb47b3319ca5516780996623a5390886c7f80773d3ec794742a4c0de978805085d5ee81"
    },
    {
      "line": 102,
      "relation": "decreases",
      "evidence": "BI-3 also potentially inhibited the release of sAPPb (IC50 = 0.5 mM) and sAPPa (IC50 = 3.4 mM, Figs. 2B and 3B). BI- 4, which is short peptide of BI-3, showed no effects on sAPP secretion.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 6,
      "target": 2,
      "key": "62cf711b0b29c1bfcdd27c8b71f1790ab007e5e336ba25622a7884cca958f14cc8b6939b78a636648ee409c22417b0e110baa5eace4a9a0ad335cd5ea5cfc1d0"
    },
    {
      "line": 114,
      "relation": "increases",
      "evidence": "Surprisingly, BI-1 treatment resulted in a drastic, dose-dependent increase in the level of intracellular APPa (Figs. 2A and 3A). BI-3 also induced the accumulation of intracellular APPa until the concentration of BI-3 was raised to 12.5 mM; however, treatment of BI-3 with 25 mM decreased the level of intracellular APPa.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "intracellular"
        }
      },
      "source": 6,
      "target": 2,
      "key": "54345b73b5150bf591ec6f0bbfd7547da22371f768a15c62f1f456545f5355e01f7f580389e354426ecfaeed23b320e8e0af7d5e49f5658830340b98882452d5"
    },
    {
      "line": 139,
      "relation": "increases",
      "evidence": "Taken together, these results show that BI-1 and BI-3 not only selectively reduce the level of APPbeta but also lead to the accumulation of APPalpha in cells with no change of full-length APP level.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 6,
      "target": 2,
      "key": "532bc57ab0b3d0aa3eedaca09c8329e328282b4e787e7d60fbebc993acb836a9a5fda6bd683127f2da75db46185b283b22826347358dd2b09d8db205bcc26cf1"
    },
    {
      "line": 123,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 6,
      "target": 1,
      "key": "0e1cc6f9dca7fe63db03ebb532ac703e99109b484baa880f34a70f7627f4e2c957345992fc6c89a1397cefb3e27e8a5d631d678e0aa63c7bd41fbd079489c9c7"
    },
    {
      "line": 128,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 6,
      "target": 4,
      "key": "ea18b9e5b552d593798c732e8e6127b7a3228aa94c488404cfb63b92cb677ba22b04c1650c6c976f1f8ff39fa7235d2008bdf37aa063aff7603d642f07b5d2a6"
    },
    {
      "line": 146,
      "relation": "causesNoChange",
      "evidence": "These results suggest that BACE1 derived peptides do not directly inhibit BACE activities in vitro when the fluorogenic peptides are used as a substrate.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 5,
      "key": "0e0b83631c96e9a89fa99c180bb9e0689ab21d881e0725f035819e03c8a698c2e337df11fc30c08434aad3041fcb654de13422ca261767415616b2411f84f751"
    },
    {
      "line": 156,
      "relation": "decreases",
      "evidence": "BI-1 treatment effectively reduced Ab 40 levels (IC50 = 0.06 mM) in the conditioned medium. BI-3 also inhibited Ab 40 production (IC50 = 0.2 mM), although the effective concentrations were relatively high compared to those of BI-1.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 6,
      "target": 0,
      "key": "514c22599213af494eb6d0f32463368994313a2b4806b977e2104cf3e92821ff8e52eb60324c83b55338aa2ccd924af747504d2aeaaec6034741adc55b530631"
    },
    {
      "line": 103,
      "relation": "causesNoChange",
      "evidence": "BI-3 also potentially inhibited the release of sAPPb (IC50 = 0.5 mM) and sAPPa (IC50 = 3.4 mM, Figs. 2B and 3B). BI- 4, which is short peptide of BI-3, showed no effects on sAPP secretion.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 7,
      "target": 3,
      "key": "f38f4a0452340d447771cf3be687bc29f1259eefa92d17faf1c955a37ab91a645bb4286c8eda661b316602ef1fa63e4b87888b0f74814aa55103fe463a0a91ab"
    },
    {
      "line": 104,
      "relation": "causesNoChange",
      "evidence": "BI-3 also potentially inhibited the release of sAPPb (IC50 = 0.5 mM) and sAPPa (IC50 = 3.4 mM, Figs. 2B and 3B). BI- 4, which is short peptide of BI-3, showed no effects on sAPP secretion.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 7,
      "target": 2,
      "key": "3ada04045c7666648a38dad9366a4fa762ff09a8d640954e5ee0972b654eaf093114bf10c41f00584f5a41a8170140fb775a6decda7b1dc0bdbf8547f73db7df"
    },
    {
      "line": 124,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 7,
      "target": 1,
      "key": "90345cb478bdb690fff4050f478da3c35989f367b57e7acf8c8ebfc51423f9d541c61e3ad389ad369ca3602ec0123cfe26f3942f60648e266c19dc5be80ae346"
    },
    {
      "line": 129,
      "relation": "causesNoChange",
      "evidence": "Neither, BI-1 nor, BI-3, nor any of the other peptides used in this study, induced any changes of full-length APP levels. They also did not affect the level of b-actin.",
      "citation": {
        "type": "PubMed",
        "reference": "17293005"
      },
      "source": 7,
      "target": 4,
      "key": "b4e54519693310c31b530cdadeccb8743613d986feac5b4cc485785709d627d617e61e2a436619ca9eb086972cc8a483c77b067454217556c85ee8ad9f2f4fcc"
    }
  ]
}